187 related articles for article (PubMed ID: 19752336)
1. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
2. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
[TBL] [Abstract][Full Text] [Related]
3. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
4. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
5. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
6. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity.
Tian H; He Y; Song X; Jiang L; Luo J; Xu Y; Zhang W; Gao X; Yao W
Cancer Lett; 2018 Aug; 430():79-87. PubMed ID: 29778570
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001.
Wiedermann U; Garner-Spitzer E; Chao Y; Maglakelidze M; Bulat I; Dechaphunkul A; Arpornwirat W; Charoentum C; Yen CJ; Yau TC; Tanasanvimon S; Maneechavakajorn J; Sookprasert A; Bai LY; Chou WC; Ungtrakul T; Drinic M; Tobias J; Zielinski CC; Chong L; Ede NJ; Marino MT; Good AJ
Clin Cancer Res; 2021 Jul; 27(13):3649-3660. PubMed ID: 33879458
[TBL] [Abstract][Full Text] [Related]
8. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
10. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
11. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
[TBL] [Abstract][Full Text] [Related]
13. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
14. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
Kaumaya PT
Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
[TBL] [Abstract][Full Text] [Related]
15. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
16. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
[TBL] [Abstract][Full Text] [Related]
18. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
19. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
[TBL] [Abstract][Full Text] [Related]
20. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
